To investigate whether trimebutine can prevent the growth of glioma/glioblastoma cells through the inhibition of p-ERK and p-AKT, western blot was performed to analyze the protein levels of p-ERK and p-AKT in SHG44, U251 andU-87 MG cells in response to trimebutine treatment (50, 100, and 200 μM) for 48 and 72 h. Here, AKT1 is linked to glioma.